Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenx	$532.27 -1.9%	$592.11	$356.38 ▼ $678.21	$32.50B	0.57	321,553 shs	486,197 shs
BNTX BioNTech	$92.08 -2.6%	$97.78	$76.53 ▼ $131.49	$22.10B	1.35	926,441 shs	628,909 shs
CTLT Catalent	$63.48	$62.87	$53.51 ▼ $63.50	$11.52B	1.15	1.96 million shs	N/A
TAK Takeda Pharmaceutical	$13.69 -0.2%	$14.80	$12.58 ▼ $15.43	$43.56B	0.26	1.91 million shs	2.73 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenx	-1.88%	-14.51%	-12.22%	-18.28%	+49.51%
BNTX BioNTech	-2.56%	-0.78%	-10.03%	-25.00%	-0.22%
CTLT Catalent	0.00%	0.00%	0.00%	0.00%	+14.34%
TAK Takeda Pharmaceutical	-0.29%	-9.10%	-4.20%	+0.48%	+1.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenx	3.9574 of 5 stars	4.5	2.0	0.0	0.0	3.8	1.7	1.9
BNTX BioNTech	3.0798 of 5 stars	4.4	2.0	0.0	0.0	3.4	0.8	0.6
CTLT Catalent	0.962 of 5 stars	1.0	0.0	0.0	4.6	0.0	0.0	1.9
TAK Takeda Pharmaceutical	2.8248 of 5 stars	0.0	4.0	2.5	0.0	2.5	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenx	2.96	Moderate Buy	$698.11	31.16% Upside
BNTX BioNTech	2.89	Moderate Buy	$142.08	54.31% Upside
CTLT Catalent	2.00	Hold	$63.33	-0.23% Downside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest CTLT, TAK, ARGX, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $134.00
5/14/2025	ARGX argenx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$699.00
5/14/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/13/2025	ARGX argenx	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$680.00 ➝ $680.00
5/9/2025	ARGX argenx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$704.00 ➝ $708.00
5/9/2025	ARGX argenx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,100.00 ➝ $1,065.00
5/9/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$796.00 ➝ $803.00
5/6/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $140.00
5/6/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$140.00 ➝ $132.00
4/17/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$681.00 ➝ $796.00
4/11/2025	ARGX argenx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00 ➝ $715.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenx	$2.58B	12.60	N/A	N/A	$69.22 per share	7.69
BNTX BioNTech	$2.75B	8.05	$3.96 per share	23.25	$92.17 per share	1.00
CTLT Catalent	$4.38B	2.63	$2.64 per share	24.04	$19.91 per share	3.19
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.21 per share	4.27	$15.39 per share	0.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenx	-$295.05M	$16.21	N/A	49.06	N/A	-2.11%	-1.45%	-1.29%	7/24/2025 (Estimated)
BNTX BioNTech	$1.01B	-$3.40	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	N/A
CTLT Catalent	-$1.04B	-$2.26	N/A	47.02	2.69	-9.28%	-0.66%	-0.24%	N/A
TAK Takeda Pharmaceutical	$994.06M	$0.22	34.23	8.30	0.24	4.53%	9.39%	4.53%	7/30/2025 (Estimated)

Latest CTLT, TAK, ARGX, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ARGX argenx	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
3/10/2025	Q4 2024	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/27/2025	Q4 2024	ARGX argenx	$0.98	$1.58	+$0.60	$11.79	$678.52 million	$761.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenx	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.66%	N/A	N/A	N/A
CTLT Catalent	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.53	3.87%	-8.36%	240.91%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenx	N/A	8.53	7.88
BNTX BioNTech	0.01	7.33	7.21
CTLT Catalent	1.38	2.51	1.96
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenx	60.32%
BNTX BioNTech	15.52%
CTLT Catalent	N/A
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenx	2.43%
BNTX BioNTech	19.20%
CTLT Catalent	0.31%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenx	650	61.06 million	59.29 million	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
CTLT Catalent	16,900	181.51 million	180.95 million	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

CTLT, TAK, ARGX, and BNTX Headlines

Recent News About These Companies

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

May 14 at 5:03 PM | businesswire.com

Takeda Pharmaceutical (NYSE:TAK) Shares Gap Down - Should You Sell?

May 14 at 2:47 PM | marketbeat.com

Ethic Inc. Sells 113,512 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 13 at 6:32 AM | marketbeat.com

Northern Trust Corp Purchases 238,161 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 13 at 3:48 AM | marketbeat.com

Asia-Pacific stocks mixed as investors parse China data, await Washington-Beijing trade talks

May 12 at 6:29 PM | nbcnewyork.com

Trump says he will sign order linking U.S. drug prices to other nations’

May 12 at 6:29 PM | msn.com

Takeda Pharmaceutical (NYSE:TAK) Announces Earnings Results

May 12 at 11:28 AM | marketbeat.com

Trump's plan to slash US prescription drugs costs sparks pharma stocks fears

May 12 at 8:28 AM | irishexaminer.com

Trump to sign executive order slashing drug prices today: Asian pharma stocks fall, analysts flag downsides

May 12 at 8:28 AM | invezz.com

Asian pharma stocks tumble on Trump signal to cut U.S. drug prices

May 12 at 8:28 AM | japantimes.co.jp

Pharmaceutical Stocks Tumble as Trump Plans US Drug Price Cuts

May 12 at 8:28 AM | msn.com

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

May 12 at 8:28 AM | finance.yahoo.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Ellevest Inc.

May 12 at 6:01 AM | marketbeat.com

Asia’s pharma stocks drop as Trump plans US drug price cuts

May 11, 2025 | cnbctv18.com

Trump Seeks to Align US Drug Costs With Cheapest Ones Abroad

May 11, 2025 | msn.com

Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise

May 11, 2025 | seekingalpha.com

Cubist Systematic Strategies LLC Acquires New Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 11, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Has $865,000 Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 11, 2025 | marketbeat.com

Takeda Pharmaceutical (NYSE:TAK) Updates FY 2025 Earnings Guidance

May 10, 2025 | marketbeat.com

Takeda to Invest $30B into U.S. Operations

May 9, 2025 | contractpharma.com

Takeda Pharmaceutical to invest $30bn in US over 5 years: CEO

May 9, 2025 | asia.nikkei.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Aerospace and Defense Stocks Take Flight After Strong Earnings
By Leo Miller | April 29, 2025
View Aerospace and Defense Stocks Take Flight After Strong Earnings
Is Intel Stock a Bargain or a Burden? Cheap Stock, High Stakes
By Jeffrey Neal Johnson | May 7, 2025
View Is Intel Stock a Bargain or a Burden? Cheap Stock, High Stakes
CrowdStrike Stock Is a Buy as Cyberthreat Environment Expands
By Chris Markoch | April 15, 2025
View CrowdStrike Stock Is a Buy as Cyberthreat Environment Expands
XPO Buying $50 Million of Its Own Stock: Here's Why
By Gabriel Osorio-Mazilli | April 16, 2025
View XPO Buying $50 Million of Its Own Stock: Here's Why
Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
By Leo Miller | April 18, 2025
View Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?

CTLT, TAK, ARGX, and BNTX Company Descriptions

argenx NASDAQ:ARGX

$532.27 -10.20 (-1.88%)

As of 05/14/2025 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$92.08 -2.42 (-2.56%)

As of 05/14/2025 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Takeda Pharmaceutical NYSE:TAK

$13.69 -0.03 (-0.22%)

As of 05/14/2025 03:48 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time